AU780771B2 - Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them - Google Patents

Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them Download PDF

Info

Publication number
AU780771B2
AU780771B2 AU27376/01A AU2737601A AU780771B2 AU 780771 B2 AU780771 B2 AU 780771B2 AU 27376/01 A AU27376/01 A AU 27376/01A AU 2737601 A AU2737601 A AU 2737601A AU 780771 B2 AU780771 B2 AU 780771B2
Authority
AU
Australia
Prior art keywords
sertraline hydrochloride
sertraline
hydrochloride form
solvent
suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU27376/01A
Other languages
English (en)
Other versions
AU2737601A (en
Inventor
Judith Aronhime
Marioana Mendelovici
Tamar Nidam
Claude Singer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of AU2737601A publication Critical patent/AU2737601A/en
Application granted granted Critical
Publication of AU780771B2 publication Critical patent/AU780771B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU27376/01A 1999-12-21 2000-12-21 Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them Ceased AU780771B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US17134199P 1999-12-21 1999-12-21
US60/171341 1999-12-21
US18733600P 2000-03-06 2000-03-06
US60/187336 2000-03-06
US18791000P 2000-03-08 2000-03-08
US60/187910 2000-03-08
US19060300P 2000-03-20 2000-03-20
US60/190603 2000-03-20
PCT/US2000/035178 WO2001045692A1 (en) 1999-12-21 2000-12-21 Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them

Publications (2)

Publication Number Publication Date
AU2737601A AU2737601A (en) 2001-07-03
AU780771B2 true AU780771B2 (en) 2005-04-14

Family

ID=27496950

Family Applications (1)

Application Number Title Priority Date Filing Date
AU27376/01A Ceased AU780771B2 (en) 1999-12-21 2000-12-21 Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them

Country Status (19)

Country Link
US (2) US6452054B2 (US06858652-20050222-C00002.png)
EP (2) EP1248605B1 (US06858652-20050222-C00002.png)
JP (2) JP4057295B2 (US06858652-20050222-C00002.png)
KR (1) KR100791872B1 (US06858652-20050222-C00002.png)
CN (1) CN1434708A (US06858652-20050222-C00002.png)
AT (1) ATE354358T1 (US06858652-20050222-C00002.png)
AU (1) AU780771B2 (US06858652-20050222-C00002.png)
DE (1) DE60033566T2 (US06858652-20050222-C00002.png)
DK (1) DK1248605T3 (US06858652-20050222-C00002.png)
ES (1) ES2281374T3 (US06858652-20050222-C00002.png)
HR (1) HRP20020543A2 (US06858652-20050222-C00002.png)
HU (1) HUP0204010A3 (US06858652-20050222-C00002.png)
IL (1) IL150332A0 (US06858652-20050222-C00002.png)
IS (1) IS6425A (US06858652-20050222-C00002.png)
PL (1) PL356452A1 (US06858652-20050222-C00002.png)
PT (1) PT1248605E (US06858652-20050222-C00002.png)
SK (1) SK8872002A3 (US06858652-20050222-C00002.png)
WO (1) WO2001045692A1 (US06858652-20050222-C00002.png)
YU (1) YU47902A (US06858652-20050222-C00002.png)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5845313A (en) 1995-07-31 1998-12-01 Lexar Direct logical block addressing flash memory mass storage architecture
US6978342B1 (en) 1995-07-31 2005-12-20 Lexar Media, Inc. Moving sectors within a block of information in a flash memory mass storage architecture
US6500987B1 (en) * 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
US6495721B1 (en) * 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
TWI260315B (en) 1999-10-29 2006-08-21 Ciba Sc Holding Ag Polymorphic forms of sertraline hydrochloride
SK8872002A3 (en) 1999-12-21 2002-12-03 Teva Pharma Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
US6552227B2 (en) * 2000-03-14 2003-04-22 Teva Pharmaceutical Industries Ltd. Process for preparing (+)-cis-sertraline
WO2002096860A1 (en) * 2001-05-31 2002-12-05 Orion Corporation Fermion Process for preparing sertraline intermediates
WO2002096859A1 (en) 2001-05-31 2002-12-05 Orion Corporation Fermion Process for preparing sertraline hydrochloride polymorphic form ii
GB0123421D0 (en) 2001-09-28 2001-11-21 Memquest Ltd Power management system
US6897340B2 (en) 2002-04-29 2005-05-24 Teva Pharmaceutical Industries Ltd. Processes for preparation of polymorphic form II of sertraline hydrochloride
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20040131672A1 (en) * 2003-01-07 2004-07-08 Nilobon Podhipleux Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties
JP2007502329A (ja) 2003-05-23 2007-02-08 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド セルトラリン組成物
CA2537804A1 (en) * 2003-09-05 2005-03-17 Teva Pharmaceutical Industries Ltd A recycling process for preparing sertraline
ZA200603502B (en) * 2003-11-04 2008-02-27 Cipla Ltd Process for the preparation of polymorphs of selective serotonin reuptake inhibitor
US7464306B1 (en) 2004-08-27 2008-12-09 Lexar Media, Inc. Status of overall health of nonvolatile memory
US7345201B2 (en) * 2005-02-23 2008-03-18 Teva Pharmaceutical Industries, Ltd. Processes for preparing sertraline
WO2006103506A1 (en) * 2005-03-31 2006-10-05 Ranbaxy Laboratories Limited Sertraline-containing pharmaceutical compositions and a process for preparation thereof
GB0507090D0 (en) * 2005-04-07 2005-05-11 Sandoz Ag Process for preparing polymorphic form ll of sertraline hydrochloride
US7518019B2 (en) * 2006-06-01 2009-04-14 Hetero Drugs Limited Processes for preparing sertraline hydrochloride crystalline forms
US20060257475A1 (en) * 2006-08-17 2006-11-16 Boehringer Ingelheim International Gmbh Stable Sertraline Hydrochloride Formulation and Method
CA2594198A1 (en) * 2007-07-20 2009-01-20 Apotex Pharmachem Inc. A novel process for the preparation of sertraline hydrochloride form ii
FR2928148B1 (fr) * 2008-02-28 2013-01-18 Sanofi Aventis Procede de preparation de combretastatine
KR102495018B1 (ko) 2013-11-15 2023-02-06 아케비아 테라퓨틱스 인코포레이티드 ｛[5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐]아미노｝아세트산의 고체형, 이의 조성물 및 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US6452054B2 (en) * 1999-12-21 2002-09-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
US6500987B1 (en) * 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US5082970A (en) 1991-03-06 1992-01-21 Pfizer Inc. Process for recycling amine isomer
GB9114947D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline
US5734083A (en) 1996-05-17 1998-03-31 Torcan Chemical Ltd. Sertraline polymorph
JP2002506844A (ja) 1998-03-18 2002-03-05 チバ スペシャルティ ケミカルズ ホールディング インコーポレーテッド シクロヘキシリデンアミンのｃｉｓ−選択的接触水素化方法
JP2000026379A (ja) * 1998-07-08 2000-01-25 Sumika Fine Chemicals Co Ltd 塩酸セルトラリンメタノール和物および塩酸セルトラリンエタノール和物、ならびにそれらの製法
EP1133459B1 (en) * 1998-11-27 2006-01-11 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride form v
US6495721B1 (en) 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
TWI260315B (en) * 1999-10-29 2006-08-21 Ciba Sc Holding Ag Polymorphic forms of sertraline hydrochloride
IN192343B (US06858652-20050222-C00002.png) 2000-05-26 2004-04-10 Ranbaxy Lab Ltd

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US6500987B1 (en) * 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
US6452054B2 (en) * 1999-12-21 2002-09-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them

Also Published As

Publication number Publication date
DE60033566D1 (de) 2007-04-05
EP1248605B1 (en) 2007-02-21
US20030023117A1 (en) 2003-01-30
EP1797875A3 (en) 2007-08-29
HRP20020543A2 (en) 2005-04-30
KR20020062356A (ko) 2002-07-25
US6858652B2 (en) 2005-02-22
IL150332A0 (en) 2002-12-01
EP1248605A2 (en) 2002-10-16
HUP0204010A2 (hu) 2003-04-28
ES2281374T3 (es) 2007-10-01
WO2001045692A9 (en) 2002-07-04
PT1248605E (pt) 2007-03-30
JP4057295B2 (ja) 2008-03-05
DE60033566T2 (de) 2007-10-25
US20010041815A1 (en) 2001-11-15
IS6425A (is) 2002-06-18
US6452054B2 (en) 2002-09-17
WO2001045692A1 (en) 2001-06-28
DK1248605T3 (da) 2007-03-19
JP2007308505A (ja) 2007-11-29
CN1434708A (zh) 2003-08-06
JP2003518056A (ja) 2003-06-03
EP1248605A4 (en) 2004-11-24
SK8872002A3 (en) 2002-12-03
KR100791872B1 (ko) 2008-01-07
EP1797875A2 (en) 2007-06-20
AU2737601A (en) 2001-07-03
HUP0204010A3 (en) 2006-02-28
ATE354358T1 (de) 2007-03-15
PL356452A1 (en) 2004-06-28
YU47902A (sh) 2005-11-28

Similar Documents

Publication Publication Date Title
AU780771B2 (en) Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
US20210002227A1 (en) Crystalline forms of pitavastatin calcium
US20070093557A1 (en) Sertraline hydrochloride form II and methods for the preparation thereof
US20070238738A1 (en) Crystalline ziprasidone HCI and processes for preparation thereof
EP2041083A1 (en) Zofenopril calcium
EP1774965A2 (en) Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
ZA200204971B (en) Sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them.
WO2007016209A2 (en) Pure 1,2-benzisoxazole-3-methane-sulfonic acid sodium salt and purification process